Mark Davis, ND. Fecal microbiota transplantation (FMT) is also known as human probiotic infusion, fecal transplant, fecal bacteriotherapy, fecal slurry, and gut flora rehabilitation and has been humorously referred to as transpoosion. The procedure consists of collecting stool from a healthy donor; suspending it in water, normal saline, or 4% milk; and administering it to the patient (most frequently via enema but also via colonoscope, nasogastric or nasoduodenal tube, rectal tube, or even [anecdotally] orally as a milkshake1). This massive infusion of healthy colonic bacteria has been used as far back as the 17th century in veterinary medicine to treat digestive disturbances2 and as early as 1958 in humans to treat pseudomembranous colitis.3. Fecal microbiota transplantation has a 90% success rate in curing Clostridium difficile-associated chronic diarrhea, colitis, and pseudomembranous colitis,4 which affect half a million and kill 15 000 to 20 000 Americans per year.5 Fecal microbiota ...
TY - JOUR. T1 - Fecal microbiota transplantation for recurrent Clostridium difficile infection. AU - Brandt, Lawrence J.. AU - Reddy, Sheela S.. PY - 2011/11. Y1 - 2011/11. N2 - With the increasing prevalence of recurrent/refractory Clostridium difficile infection (CDI), alternative treatments to the standard antibiotic therapies are being sought. One of the more controversial of such alternative treatments is fecal microbiota transplantation (FMT). Although the notion of FMT is foreign - even startling - and not esthetic to most people, the concept has been around for many decades. Its benefit and efficacy dates back ,50 years to its use for staphylococcal pseudomembranous colitis, and now FMT is showing a great promise as an inexpensive, safe, and highly efficient treatment for recurrent and refractory CDI. Moreover, with a better understanding of the intricacies of the colonic microbiome and its role in colonic pathophysiology, FMT has the potential to become the standard of care for CDI ...
Fecal microbiota transplantation (FMT) involves administering fecal material from a healthy individual into the gastrointestinal tract of the patient. This has been done in the past for recurrent colitis secondary to Clostridium difficile infection (CDI) using different methods such as through nasogastric tube, fecal retention enemas, and by colonoscopy. This method of treatment was introduced over 50 years ago with high success rates, although it has not been until recent that more case studies have been performed, with continued success rates of approximately 90%. Studies have found this therapy to be effective with resolution of symptoms in most patients, and have found it to be both cost effective and safe.. The purpose of this study is to use a standardized published protocol for fecal microbiota transplantation performed by colonoscopy and record the success rate and outcomes of FMT therapy for patients with recurrent CDI at the UMassMemorial Medical Center. In addition, the cost of this ...
The investigators propose to use autologous fecal microbiota transplantation (AFMT) to acute myeloid leukemia (AML) patients treated with intensive chemotherapy and antibiotics in order to restore the balance of their intestinal microbiome and thereby eradicate treatment-induced multidrug resistant bacteria (MDRB), infection-related complications, as well as sequelae to the gastrointestinal tract. Therefore, the investigators propose to perform a single-arm multicentre prospective fecal microbiota transplantation (FMT) trial in AML patients receiving intensive chemotherapy, and who are usually heavily treated with broad-spectrum antibiotics during aplasia that generate a profound status of dysbiosis. For this purpose, at the time of admission and AML diagnosis, patients will be requested to donate stools that will be comprehensively screened, and if deemed appropriate according to protocol criteria, conditioned and stored frozen until future processing and transplantation after aplasia completion ...
Post written by Jessica R. Allegretti, MD, MPH, from Brigham Womens Hospital, Boston, Massachusetts, USA. Clostridium difficile infection (CDI) is the most common healthcare-associated infection in the United States. Recently, fecal microbiota transplantation (FMT) has emerged as an effective and safe therapy for recurrent CDI; however, there is no standardized clinical approach. Given the rapid…
Dysbiosis plays a major role in the etiology of inflammatory bowel disease (IBD). Fecal microbiota transplantation (FMT) is a new promising option for IBD treatment. We aimed to assess the effectivene
Phys.org Science News Wire : Largest Planned Fecal Microbiota Transplantation (FMT) study enrolls first patient -- a press release is provided to you ìas isî with little or no review from Phys.org staff.
VENTURA, Calif., Oct 26, 2020 (SEND2PRESS NEWSWIRE) - The American College of Gastroenterology (ACG) named Progenabiome Outstanding Poster Presenter for its poster: Successful Bacterial Engraftment Identified by Next Generation Sequencing Following Fecal Microbiota Transplantation for Clostridioides difficile Infection, which will be presented virtually at the ACG Annual Scientific Meeting this week. From close to 2900 posters, only roughly 10% were selected as outstanding posters.. Progenabiome will also present a second poster: Detection and Mutational Analysis of SARS-CoV-2 From Patient Fecal Samples by Whole Genome Sequencing. The ACG 2020 Meeting will be held virtually on October 23-28, 2020, and both poster abstracts and presentations will be available online in the ACG 2020 ePoster Hall. Last year, Dr. Sabine Hazan, CEO of Progenabiome, shared groundbreaking data on C.Diff discovered through genetic sequencing at the 2019 ACG Meeting. She is looking forward to sharing newly found ...
NIAID-supported researchers have shown that autologous fecal microbiota transplantation (auto-FMT) is a safe, effective way to replenish beneficial gut bacteria in cancer patients requiring intense antibiotics during allogenic hematopoietic stem cell transplantation. Auto-FMT resulted in the recovery of beneficial gut bacteria to near baseline levels within days, restoring digestive, immune and other functions. With standard care, beneficial bacteria typically take weeks to recover from antibiotic treatment, leaving patients at risk of other infectious diseases.
Biological therapies in the systemic management of psoriasis; International Consensus Conference. Br J Dermatol, 151 (2004), pp. 3-17. Medline. 4. D. Thaci. Cosentyx is the only biologic that can be used as first-line systemic therapy in the treatment of psoriasis and as an alternative to treatments that have significant side effects 1; all other biologics are recommended for second-line therapy 2-4. Currently, all biologic treatments for psoriasis, including anti-tumor necrosis factor therapies (anti-TNFs) and Stelara (ustekinumab) are recommended for second-line systemic therapy in Europe 2-4. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Article September 2004 British Journal of Dermatology. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol. 2004;151 Suppl 69:3-17. Biologic agents ...
Biological therapy is a treatment that uses your bodys immune system to fight cancer cells rather than attacking those cells directly. For carefully selected people, biological therapy may target cancer cells to avoid damage to normal cells, prevent or slow tumor growth, and prevent the spread of cancer cells. Although it can have side effects, typically this type of therapy is less invasive and less toxic than conventional cancer treatments are. Biological therapy for cancer includes immunotherapy, targeted therapy and therapy that inhibits the growth of blood vessels (anti-angiogenesis).
Bladder Cancer Biological Therapy India,Cost Biological Therapy India, Bladder Cancer In India Offers Info On Cost Bladder Cancer Surgery India, Bladder Cancer Treatment Hospital Mumbai India, Bladder Cancer Surgeons India Mumbai Bangalore, Bladder Cancer Center India, Bladder Cancer Doctors India
Biological therapy is used treat certain types of non-Hodgkin lymphoma. Learn how and when biological therapy is used and side effects of biological therapy.
FMT as a treatment modality has also been tested in a range of other diseases, such as inflammatory bowel disease (IBD), irritable bowel syndrome, obesity and metabolic syndrome, as well as neurological and psychological disorders, although most reports of the latter category are merely anecdotal. Yet, the results so far are not convincing. Reports about using FMT to treat IBD patients show considerable heterogeneity in terms of clinical effect (Moayyedi et al, 2015), whereas efficacy in patients with metabolic syndrome was transient. Insulin resistance improved 6 weeks after the FMT, but at 12 weeks, no significant effect was observed anymore on metabolic parameters and fecal microbiota composition (Vrieze et al, 2012).. The reason why FMT has such variable efficacy is probably due to the stability and resilience of the gut microbiota. CDI patients who have been treated multiple times with antibiotics have most of their bacterial diversity wiped out; FMT effectively repopulates this vacated ...
Clin Gastroenterol Hepatol. 2011 Dec;9(12):1044-9. doi: 10.1016/j.cgh.2011.08.014. Epub 2011 Aug 24. Research Support, N.I.H., Extramural; Research Support, Non-U.S. Govt; Review
Key takeaways from Randi Lundbergs review of the pros and cons of using antibiotic-treated or germ-free mice in fecal microbiota transplant studies.
Fecal microbiota transplantation is reportedly the most effective therapy for relapsing Clostridium Difficile infection and a potential therapeutic option for many diseases. It also poses important ethical concerns. This study is an attempt to assess clinicians perception and attitudes towards ethical and social challenges raised by fecal microbiota transplantation. A questionnaire was developed which consisted of 20 items: four items covered general aspects, nine were about ethical aspects such as informed consent and privacy issues, four concerned social and regulatory issues, (...) and three were about an FMT bank. This was distributed to participants at the Second China gastroenterology and FMT conference in May 2015. Basic descriptive statistical analyses and simple comparative statistical tests were performed. Nearly three quarters of the 100 respondents were gastro-enterologist physicians. 89% of all respondents believed FMT is a promising treatment modality for some diseases and 88% of ...
The high concentration of bacteria may be due to the fact that cats are, as you know, obligate carnivores. They have to eat the flesh of prey. The short intestinal tract of the cat would also seem to make it more important to have more bacteria in the gut. As consequence, some scientists think that if a cat is fed a high-protein, low carbohydrate diet matching the diet of the wild cat they are less likely to develop IBD.. The fact of the matter is that if scientists believe that bacteria in the gut plays a role in IBD then I would suggest that FMT is an ideal candidate has a form of treatment for this illness because FMT would replace, wholesale, the bad bacteria in the intestinal tract of the cat with the faecal bacteria of a healthy cat.. As for humans, FMT as a treatment for the management of IBD has been proved successful in studies. The success rate was high. In the 17 patients in whom it was reported, 13/17 ceased IBD medications within 6 weeks. All experienced symptom reduction or ...
Introduction. There is a growing body of evidence highlighting the possible interactions between the microbiota and cancer. However, little is known about the consequence on the microbiota of the intensive chemotherapy in patients with AML. Indeed, intensive treatments of AML are known to negatively impact gut microbiota composition; it is measured by a deep shutdown of diversity indices (eg. Simpson), also called dysbiosis. Decrease in microbiota diversity may impact the immune system and may have consequences on the outcome of AML patients. Therefore, development of strategies to manipulate the gut microbiota may minimize treatment-related complications and potentially improve outcomes. With this background, we developed a single arm prospective phase I/II multicenter trial (ClinicalTrials.gov Identifier: NCT02928523) aiming to evaluate use of auto-FMT in AML patients treated with intensive chemotherapy and antibiotics. Patients and methods. For this purpose, at the time of admission and AML ...
A 32-year-old Chinese man developed severe enterocolonic CD where he was hospitalized in 2012 for progressive abdominal pain, bloody and purulent diarrhea and high fever of 38 °C-39.5 °C. He was diagnosed in 2010 and managed his disease through daily intravenous medicines. A CT Scan showed an abdominal mass of size 14 cm × 8 cm × 10 cm. His sigmoid colon was severely inflamed and he was given intravenous antiobiotics for 10 days but frequently experienced fever and abdominal pain; plus, the abdominal mass size was unchanged. After the patient expressed interest in a clinical trial, various tests were conducted and the donor found was his 10-year-old, healthy daughter. A week after FMT, his previous symptoms were dramatically alleviated and the size of inflamed mass was reduced. Additionally, the CDAI score was reduced to 228. He had a severe cold in the whole third week after he was discharged with clinical improvement. At one month of follow-up after FMT, his CDAI score was further reduced ...
A 32-year-old Chinese man developed severe enterocolonic CD where he was hospitalized in 2012 for progressive abdominal pain, bloody and purulent diarrhea and high fever of 38 °C-39.5 °C. He was diagnosed in 2010 and managed his disease through daily intravenous medicines. A CT Scan showed an abdominal mass of size 14 cm × 8 cm × 10 cm. His sigmoid colon was severely inflamed and he was given intravenous antiobiotics for 10 days but frequently experienced fever and abdominal pain; plus, the abdominal mass size was unchanged. After the patient expressed interest in a clinical trial, various tests were conducted and the donor found was his 10-year-old, healthy daughter. A week after FMT, his previous symptoms were dramatically alleviated and the size of inflamed mass was reduced. Additionally, the CDAI score was reduced to 228. He had a severe cold in the whole third week after he was discharged with clinical improvement. At one month of follow-up after FMT, his CDAI score was further reduced ...
Key Points. Bacterial diversity was restored after FMT with oral frozen capsules, with improvement of diarrhea.Oral FMT for steroid-refractory acute gGVHD is f
Professor Borody is most famous for his ground-breaking work developing the triple therapy cure for peptic ulcers in 1987, which has saved hundreds of thousands…
FMT induces remission in a significantly greater percentage of patients with active UC than placebo, with no difference in adverse events. Fecal donor and time of UC appear to affect outcomes. ClinicalTrials.gov Number: NCT01545908.
Gastroenterology & Hepatology. January 2015, Volume 11, Issue 1. Woo Jung Lee, MD, Lakshmi D. N. Lattimer, MD, Sindu Stephen, MD, Marie L. Borum, MD, and David B. Doman, MD. Dr Lee and Dr Lattimer are gastroenterology fellows in the Division of Gastroenterology and Liver Diseases at George Washington University Medical Center and are affiliated with Medical Faculty Associates, both in Washington, DC. Dr Stephen is a gastroenterologist in Silver Spring, Maryland. Dr Borum is a professor of medicine at George Washington University School of Medicine in Washington, DC and the director of the Division of Gastroenterology and Liver Diseases at George Washington University Medical Center; she is also affiliated with Medical Faculty Associates. Dr Doman is a clinical professor of medicine at George Washington University School of Medicine.. Address correspondence to: Dr David B. Doman, 12012 Veirs Mill Road, Silver Spring, MD 20906, Tel: 301-942-3550, E-mail: [email protected] Abstract: The symbiotic ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Those are great questions. I hope you get some answers. I went back and took a second look to see if the article had an online supplement where that sort of detail is often published, but as you probably saw also, they didnt.. BTW, your link got cut off. This one might work better:. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458210/. This version of the article is free to the public so anybody who wants to read it should be able to.. I think its likely that at the very least at least some people either acquire PD from their gut or their gut contributes to the condition. That may be an overly cautious assessment, but its hard to say right now.. As you probably know given your level of interest, the gut microbiome is complex, and the good news and the bad news is that for other conditions, at least, health or disease is often associated with certain metabolic capabilities rather than a particular bacterial species. Thats bad in that it makes it more difficult to assign blame to one ...
Excision BioTherapeutics, a life science company focused on the development and commercialization of advanced gene editing therapeutics for the treatment of life-threatening disease caused by neurotropic viruses, recently announced it has completed a $10 million seed round of financing, led by ARTIS Ventures. The investment will enable the company to enter into human clinical trials with its HIV-1 targeted CRISPR platform, giving Excision BioTherapeutics the first effort to fully remove/excise the HIV-1 genome from all human cells and tissues. In addition, Excision BioTherapeutics is extending this approach to other viruses by targeting their genetic elements, and eliminating them permanently from the patient. Regarding this development, Thomas Malcolm, Ph.D, Excision BioTherapeutics founder, president and CEO, stated Excisions mission has always been to advance gene editing therapeutics into safe and efficacious medicines that will eradicate or disrupt viral genes in human patients. The ...
Biological therapy (also called immunotherapy, biological response modifier therapy, or biotherapy) uses the bodys immune system to fight cancer. The cells, antibodies, and organs of the immune system work to protect and defend the body against foreign invaders, such as bacteria or viruses. Doctors and researchers have found that the immune system might also be able to both determine the difference between healthy cells and cancer cells in the body, and to eliminate the cancer cells. (By itself, the immune system is not always good at destroying cancer cells; if it were, people would not get cancer.). Biological therapies are designed to boost the immune system, either directly or indirectly, by assisting in the following:. ...
Kaltsonoudis et al.9 conducted a prospective study in 77 patients with inflammatory rheumatic disease (36 patients with rheumatoid arthritis, 24 patients with psoriatic arthritis and 17 patients with ankylosing spondylitis) who began with anti-TNFα (infliximab, adalimumab, etanercept). All underwent a complete neurological examination, nuclear magnetic resonance of the brain and the entire spine, and a neurophysiology study before and more than 18 months after starting the biological therapy. In the initial scrutiny, they detected lesions compatible with demyelinating disease in magnetic resonance in 2 patients and, thus, decided against the biological treatment. At the end of the study, 4% of the patients (3/75) showed evidence of neurological involvement: peripheral demyelinating neuropathy (2 patients) and optic neuritis. In each case, the biological therapy was interrupted and the neurological disease was treated. The neurological symptoms remitted in all the patients.9 The authors stress ...
Patients with inflammatory bowel disease who required abdominal surgery while on biologics did not have more postoperative complications than those whose biologic regimens were interrupted.13-15. The first study of patients with psoriasis or psoriatic arthritis on biologics enrolled 42 patients undergoing 77 different procedures.16 While patients who continued biologic therapy did not have higher rates of postoperative complications, those who did interrupt treatment found their underlying disease worsened. Most rheumatology associations recommend interrupting biologic therapy for at least 4 half-lives before scheduled major surgery; that criterion would involve going 4 to 6 weeks without infliximab, 6 to 8 weeks off adalimumab, 2 to 3 weeks off etanercept, and 12 to 25 weeks off ustekinumab before operations.17-19 The evidence supporting that recommendation, however, is weak; in fact, it is supported only by expert opinion.. The 2013 consensus statement of the Spanish Academy of Dermatology and ...
TY - JOUR. T1 - Advances in the biological therapy and gene therapy of malignant disease. AU - Hersh, Evan M.. AU - Stopeck, Alison T.. PY - 1997/12/1. Y1 - 1997/12/1. N2 - Biological and gene therapy of cancer have become important components of clinical cancer research. Advances in this area are based on evidence for the presence of tumor antigens, antitumor immune responses, evasion of host control by tumors, and the recognition of host defense failure in cancer patients. These mechanisms are being corrected or exploited in the development of biological and gene therapy. Over the last decade, 9 biological therapies have received Food and Drug Administration approval, and another 12 appear promising and will likely be approved in the next few years. Our approach to gene therapy has been to allogenize tumors by the direct intratumoral injection of HLA-B7/β2-microglobulin genes as plasmid DNA in a cationic lipid into patients with malignant melanoma. In four Phase I studies, we found a 36% ...
Looking for information on Biologic Therapies for Aging Discs in Bellaire? We have compiled a list of businesses and services around Bellaire that should help you with your search. We hope this page helps you find information on Biologic Therapies for Aging Discs in Bellaire.
Looking for information on Biologic Therapies for Aging Discs in Fairmont? We have compiled a list of businesses and services around Fairmont that should help you with your search. We hope this page helps you find information on Biologic Therapies for Aging Discs in Fairmont.
Asthma is a chronic and heterogenic respiratory tract disorder with a high global prevalence. The underlying chronic inflammatory process and airway remodeling (AR) contribute to the symptomatology of the disease. The most severely ill asthma patients may now be treated using a variety of monoclonal antibodies aiming key inflammatory cytokines involved in asthma pathogenesis. Although clinical data shows much beneficial effects of biological therapies in terms of reduction of exacerbation rates, improvement of lung functions, asthma control and patients quality of life, little is known on the effects of these monoclonal antibodies on AR-a key clinical trait of long-term asthma management. In this review, the authors summarize the data on the proven effects of monoclonal antibodies in asthma on AR. To date, in terms of reversing AR, the mostly studied was omalizumab. However, some studies also addressed this clinical issue in context of other severe asthma biological therapies (mepolizumab, benralizumab
Global Cancer Biologic Therapy Market- Forecast to 2021 The report firstly introduced Global Cancer Biologic Therapy Market including classification, appli
Biological therapy may be used to treat chronic myelogenous leukemia in the chronic or accelerated phase. Learn about biological therapy for CML.
Phage therapy or viral phage therapy is the therapeutic use of bacteriophages to treat pathogenic bacterial infections. Phage therapy has many potential applications in human medicine as well as dentistry, veterinary science, and agriculture. If the target host of a phage therapy treatment is not an animal, the term biocontrol (as in phage-mediated biocontrol of bacteria) is usually employed, rather than phage therapy. Bacteriophages are much more specific than antibiotics. They are typically harmless not only to the host organism, but also to other beneficial bacteria, such as the gut flora, reducing the chances of opportunistic infections. They have a high therapeutic index, that is, phage therapy would be expected to give rise to few side effects. Because phages replicate in vivo, a smaller effective dose can be used. On the other hand, this specificity is also a disadvantage: a phage will only kill a bacterium if it is a match to the specific strain. Consequently, phage mixtures are ...
...FORT WORTH Texas June 7 2011 /- Healthpoint Biotherape...The presentations will include updates on the Companys ongoing commer... About Healthpoint Biotherapeutics ...Healthpoint Biotherapeutics is a biopharmaceutical company focused on ...,Healthpoint,Biotherapeutics,to,Present,at,Upcoming,Investment,Conferences,medicine,advanced medical technology,medical laboratory technology,medical device technology,latest medical technology,Health
Title: Phage Therapy in Clinical Practice: Treatment of Human Infections. VOLUME: 11 ISSUE: 1. Author(s):Elizabeth Kutter, Daniel De Vos, Guram Gvasalia, Zemphira Alavidze, Lasha Gogokhia, Sarah Kuhl and Stephen T. Abedon. Affiliation:Lab 1, The Evergreen State College, Olympia, WA 98505, USA.. Keywords:Bacteriophages, burn care, Eliava Institute, Hirszfeld Institute, intestiphage, osteomyelitis treatment, phage therapy, purulent infections, pyophage, wound care. Abstract: Phage therapy is the application of bacteria-specific viruses with the goal of reducing or eliminating pathogenic or nuisance bacteria. While phage therapy has become a broadly relevant technology, including veterinary, agricultural, and food microbiology applications, it is for the treatment or prevention of human infections that phage therapy first caught the worlds imagination - see, especially, Arrowsmith by Sinclair Lewis (1925) - and which today is the primary motivator of the field. Nonetheless, though the first human ...
Bacteriotherapy is the use of transplanted bacteria inside of an organism. Fecal bacteriotherapy works due to bacterial interference, the process by which bacteria displace pathogens. Bioremediation Biodegradation Microbial biodegradation van Nood, E; Vrieze, A; Nieuwdorp, M; et al. (January 2013). Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile. N. Engl. J. Med. 368 (5): 407-15. doi:10.1056/NEJMoa1205037. PMID 23323867. Huovinen, Pentti (18 August 2001). Bacteriotherapy: the time has come. British Medical Journal. BMJ Group. 323 (7309): 353-354. doi:10.1136/bmj.323.7309.353. PMC 1120965 . PMID 11509411 ...
Fecal bacteriotherapy Fecal microbiota transplantation (FMT) also known as a stool transplant is the process of transplantation of fecal bacteria...
The scientific literature shows a renewed interest in phage therapy. Part of this interest stems from a series of spectacular experiments conducted with phage lysins (31, 37, 44), another part comes from a number of recent animal experiments with viable phage particles as antibacterial agents (8, 11, 14, 28, 30, 32, 49, 54), and a further part derives from historical reviews of the Soviet experience with phage therapy (4, 10, 12, 18, 48, 49, 50). It is currently difficult to critically assess the potential of the clinical trials conducted in the former Soviet Union. The trials were mainly published in Russian, most of the trials were uncontrolled, and the therapeutic phages were not described in published reports. With the present study, we wanted to address some of the basic preclinical problems of phage therapy in the context of E. coli diarrhea. We have chosen this example because a substantial body of knowledge has been accumulated on E. coli and its phages; the pathogenic target bacteria ...
This long overdue title provides a comprehensive, up-to-date, state-of-the art review of approved biologic therapies, with coverage of mechanisms of action, Indications for therapy, immunogenicity and a detailed examination of adverse effects and safety of the many and diverse therapeutic agents presented in a total of 13 chapters. It is predicted that by 2016, biologics will make up half of the worlds 20 top-selling drugs and by 2018, biologic medicine sales will account for almost half of the worlds 100 biggest selling drugs. Recombinant proteins dominate the growing list of the more than 200 approved biotherapeutic agents with targeted antibodies, fusion proteins and receptors; cytokines; hormones; enzymes; proteins involved in blood-clotting, homeostasis and thrombosis; vaccines; botulinum neurotoxins; and, more recently, biosimilar preparations, comprising the majority of approved biologics. Written with clinicians, other health care professionals, and researchers in mind, Safety of ...
Rectal bacteriotherapy, fecal microbiota transplantation or oral vancomycin treatment of recurrent Clostridium difficile infections: A randomized controlled trial. ...
Our Biologic Therapy Program focuses on the treatment of advanced melanoma and kidney cancer. Physicians, including Drs. Michael Atkins, David McDermott, James Mier, Rupal Bhatt, and Dan Cho, investigate and use biologic agents, such as cytokines and vaccines, to treat solid tumors in patients with metastatic melanoma and kidney carcinoma.
Title:Recent Advances in Probiotics as Live Biotherapeutics Against Gastrointestinal Diseases. VOLUME: 24 ISSUE: 27. Author(s):Rohini Krishna Kota, Ranga Rao Ambati*, Aswani Kumar Y.V.V., Krupanidhi Srirama and Prakash Narayana Reddy*. Affiliation:Department of Biotechnology, Vignans Foundation for Science, Technology and Research, Vadlamudi, Guntur-522213, Andhra Pradesh, Department of Biotechnology, Vignans Foundation for Science, Technology and Research, Vadlamudi, Guntur-522213, Andhra Pradesh, Department of Biotechnology, Acharya Nagarjuna University Nagarjuna Nagar, Guntur- 522510, Andhra Pradesh, Department of Biotechnology, Vignans Foundation for Science, Technology and Research, Vadlamudi, Guntur-522213, Andhra Pradesh, Department of Biotechnology, Vignans Foundation for Science, Technology and Research, Vadlamudi, Guntur-522213, Andhra Pradesh. Keywords:Gastrointestinal diseases, therapy, probiotics, biotherapeutics, Fecal Microbial Transplants (FMTs), Gut microbiota ...
Free Online Library: The Effect of Fecal Microbiota Transplantation on a Child with Tourette Syndrome.(Case Report) by Case Reports in Medicine; Health, general Antipsychotic agents Antipsychotic drugs Behavioral health care Behavioral medicine Microbiota (Symbiotic organisms) Nervous system diseases Care and treatment Tourette syndrome Tourettes syndrome
Therapeutic approaches to generalized pustular psoriasis and psoriatic arthritis are discussed separately. Data are limited on the efficacy of biologic agents other than infliximab for the treatment of erythrodermic psoriasis. Key words: drug therapy; psoriasis. Second-line systemic therapies for PPPP are the biologic agents, alefacept, adalimumab, etaner- cept, and infliximab (Fig 5). In other forms of psoriasis, the use of etanercept, as that of other biological therapies, has been published in an isolated way with satisfactory results. Keywords. Generalized pustular psoriasis-Von Zumbusch, Palmoplantar psoriasis, Hallopeau acropustulosis perstan, Erythrodermal psoriasis, Etanercept. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. Successful treatment of recalcitrant palmoplantar pustular psoriasis with sequencial use of infliximab and adalimumab. Biologic therapies, including tumor necrosis factor inhibitors, can be effective for severe ...
Omics group organizes Biotherapeutics national symposiums, conferences across the globe in association with popular Biotherapeutics associations and companies. OMICS group planned its conferences, and events in america, europe, middle east and asia pacific. locations which are popular with international conferences, symposiums and events are china, canada, dubai, uae, france, spain, india, australia, italy, germany, singapore, malaysia, brazil, south korea, san francisco, las vegas, san antonio, omaha, orlando, raleigh, santa clara, chicago, philadelphia, baltimore, united kingdom, valencia, dubai, beijing, hyderabad, bengaluru and mumbai
Pulsed Xenon Robotic Antibiotic™ Quickly Destroys Deadly Pathogens That Cause Hospital-Acquired Infections. DUBLIN, IRELAND and JOHANNESBURG, SOUTH AFRICA-(Marketwired - Sep 17, 2015) - Serenus Biotherapeutics (Serenus), which is bridging the divide between the worlds leading healthcare markets and the growing demand for access to innovative drugs and devices in the emerging nations of Africa, today said it had entered into an agreement with Xenex Disinfection Services to bring the Xenex pulsed xenon Full-Spectrum™ ultraviolet (UV) room disinfection system to Africa.. The Xenex Germ-Zapping Robot™ is the most advanced UV disinfection robot available and is used throughout hospitals, outpatient surgery centers and skilled nursing facilities in the United States, Canada and Europe. In a five minute disinfection cycle, the robot destroys contagious superbugs on surfaces through the use of high intensity pulsed xenon UV light. Designed for speed, effectiveness and ease of use, hospital ...
Get detailed information on SONNET BIOTHERAPEUTICS HLDGS INC (SONN.NQ) including stock quotes, financial news, historical charts, company background, company fundamentals, company financials, insider trades, annual reports and historical prices in the Company Factsheet.
Cancer Monthly. Ovarian Cancer treatments. Biologic therapy. Chemotherapy. University of Queensland, Brisbane, Australia. Compare therapy differences, longest survival rates, toxicity, side effects, hospitals.
Cancer Monthly. Breast Cancer treatments. Biologic therapy. Chemotherapy. Jules Bordet Institute, Brussels, Belgium. Compare therapy differences, longest survival rates, toxicity, side effects, hospitals.
From December 5th through the 16th, I was in the Bahamas receiving fecal microbiota transplantations to help rebalance my imbalanced gut. It was a unique experience and I think it could be a promising treatment strategy for many diseases in the future. So, why did I decide to undergo FMT treatment? The primary reason was that…
Fecal microbiota transplantation (FMT) has had a long history in medicine for treating a number of human diseases. As early as during the 4th century BC, FMT was used in China to treat patients with food poisoning and diarrhea. Over time, the method became obsolete, particularly after the realization that hygiene plays an important role in preventing infectious diseases. It was not until the late 1950s that FMT garnered interest again when the first reports about its use to treat fulminant enterocolitis appeared in the scientific literature. However, FMTs breakthrough as the method of choice for the treatment of persistent Clostridium difficile infection (CDI) came only after a double‐blind randomized trial (van Nood et al, 2013), which demonstrated 94% efficacy of FMT compared with 31% after conservative treatment with vancomycin. ...
The interactions between the composition of the microbiota and gut motility are bidirectional, which indicates that the microbiota play an important role in gut motor function and the gut motor function affects the diversity of microflora in the gastrointestinal tract [6]. Here, we found that the depletion of microbiota by antibiotics treatments was associated with gut motility, and its relationship might be related to 5-HT biosynthesis in the colon. And we also found that metabolism of bile acids was affected in antibiotic-treated mice, and the secondary bile acids was decreased in our study which has been demonstrated to be associated with 5-HT metabolism and gastrointestinal motility [13].. Several studies have focus on the interaction between the normal gut microbiota and gut motility. The dysfunction of gut motility has been considered to be one of the main pathophysiology in STC [31]. Recent years, fecal microbiota transplantation (FMT) has become a new therapy for functional ...
Full Text - Multiple exposures to anesthesia may increase the risk of cognitive impairment in young children. However, the mechanisms underlying this neurodevelopmental disorder remain elusive. In this study, we investigated alteration of the gut microbiota after multiple neonatal exposures to the anesthetic sevoflurane and the potential role of microbiota alteration on cognitive impairment using a young mice model. Multiple neonatal sevoflurane exposures resulted in obvious cognitive impairment symptoms and altered gut microbiota composition. Fecal transplantation experiments confirmed that alteration of the microbiota was responsible for the cognitive disorders in young mice. Microbiota profiling analysis identified microbial taxa that showed consistent differential abundance before and after fecal microbiota transplantation. Several of the differentially abundant taxa are associated with memory and/or health of the host, such as species of Streptococcus, Lachnospiraceae, and Pseudoflavonifractor. The
Clostridium difficile, commonly known as C. diff, affects nearly half a million Americans a year, and leads to several thousand fatalities, according to the CDC. This infection is difficult to treat, especially among those with an antibiotic-resistant strain, but Peter Moses, M.D., professor of medicine at the Larner College of Medicine and gastroenterologist at the UVM Medical Center, uses fecal microbiota transplantation (FMT) as a solution ...
TY - JOUR. T1 - Biological challenges of phage therapy and proposed solutions. T2 - a literature review. AU - Caflisch, Katherine M.. AU - Suh, Gina A.. AU - Patel, Robin. PY - 2019/12/2. Y1 - 2019/12/2. N2 - Introduction: In light of the emergence of antibiotic-resistant bacteria, phage (bacteriophage) therapy has been recognized as a potential alternative or addition to antibiotics in Western medicine for use in humans. Areas covered: This review assessed the scientific literature on phage therapy published between 1 January 2007 and 21 October 2019, with a focus on the successes and challenges of this prospective therapeutic. Expert opinion: Efficacy has been shown in animal models and experimental findings suggest promise for the safety of human phagotherapy. Significant challenges remain to be addressed prior to the standardization of phage therapy in the West, including the development of phage-resistant bacteria; the pharmacokinetic complexities of phage; and any potential human immune ...
Abstract. Background. Within seven days following peroral high dose infection with Toxoplasma gondii susceptible conventionally colonized mice develop acute ileitis due to an underlying T helper cell (Th) -1 type immunopathology. We here addressed whether mice harboring a human intestinal microbiota developed intestinal, extra-intestinal and systemic sequelae upon ileitis induction.. Methodology/Principal findings. Secondary abiotic mice were generated by broad-spectrum antibiotic treatment and associated with a complex human intestinal microbiota following peroral fecal microbiota transplantation. Within three weeks the human microbiota had stably established in the murine intestinal tract as assessed by quantitative cultural and culture-independent (i.e. molecular 16S rRNA based) methods. At day 7 post infection (p.i.) with 50 cysts of T. gondii strain ME49 by gavage human microbiota associated (hma) mice displayed severe clinical, macroscopic and microscopic sequelae indicating acute ileitis. ...
They proved this by fecal microbiota transplantation which involved taking a stool sample solution from the humans and administering it into the digestinal tract of mice. The human stool samples were taken before and after metformin treatment and the mice had been put on a high-calorie diet. The fecal transplant is thought to help pass good bacteria from a healthy person to someone who is unwell ...
The introduction of biologic therapies, which selectively target components of the immune system, has revolutionized the treatment of rheumatoid arthritis. Anti-TNF-alpha therapy (infliximab, etanercept and adalimumab) and B-cell-depleting agents, such as rituximab, are the most widely used agents. Increased experience of the use of biologic drugs in other immune-mediated inflammatory diseases has led to the application of biologic therapies in the treatment of primary systemic vasculitis. Conversely, the success of biological agents has improved understanding of the immunopathogenesis of vascular inflammation. The need for biologic agents arises from the failure of the current standard of care to maintain remission while limiting drug toxicity. Evidence for the efficacy of biologic agents does not match that of conventional immunosuppressants yet, but it is building rapidly. This paper reviews the current evidence for the standard of care of patients with vasculitis and the role of biologic therapy in
BACKGROUND: Axial spondyloarthropathy typically has its onset in early adulthood and can impact significantly on quality of life. In the UK, biologic anti-tumour necrosis factor therapy is recommended for patients who are unresponsive to non-steroidal anti-inflammatory drugs. There remain several unresolved issues about the long-term safety and quality of life outcomes of biologic treatment in axial spondyloarthropathy. Long-term real-world surveillance data are required to complement data from randomised controlled trials. METHODS/DESIGN: We are conducting a UK-wide prospective cohort study of patients with axial spondyloarthropathy who are naïve to biologic therapy at the time of recruitment. Those about to commence anti-tumour necrosis factor biologic therapy will enter a biologic sub-cohort with other patients assigned to a non-biologic sub-cohort. The primary objective is to determine whether the use of biologic therapy is associated with an increased risk of serious infection, while ...
BACKGROUND: Irritable bowel syndrome (IBS) is associated with intestinal dysbiosis. Therefore, faecal microbiota transplantation (FMT) has been hypothesised to have a positive effect in patients with IBS. In this study, we analysed previously unexamined data from our randomised, double-blind, placebo-controlled study (trial registration number NCT02788071). The objective was to evaluate the effect of FMT on abdominal pain, stool frequency, and stool form.. METHOD: The study included 52 adult patients with moderate-to-severe IBS assigned randomly to treatment with FMT capsules or placebo capsules (1:1) for 12 days. The patients were followed for a total of six months, during which they kept a daily symptom diary tracking their abdominal pain on a scale from 0-10 and their bowel movements using the Bristol Stool Form Scale (BSFS). Diary data were not collected before treatment start.. RESULTS: A statistically significant improvement in stool frequency was found in the FMT group from during ...
Beyond its role in therapy, FMT is providing insights into the importance of intestinal microbiota in health and disease. As physicians and scientists, we live in exciting times! Bacteria are no longer viewed solely as pathogens, but also as key partners in the maintenance of health. It is conceivable that altering the microbiota in our gastrointestinal tract may either predispose us to disease or ameliorate conditions we already have. Faecal microbiota transplantation (FMT) has captured the attention of the lay press and professional journals since 1958, when faecal enema was reported to have cured four patients near death from severe Micrococcus pyogenes colitis.1. ...
TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, announces that it has dosed its first patients and progressed to the second dose level in a monotherapy phase 1 clinical trial of TILT-123, a dual cytokine armed oncolytic adenovirus. The trial is being performed in patients with injectable solid tumors. Patients are being treated at Docrates Cancer Center and Helsinki University Hospital (Helsinki, Finland), leading international treatment facilities specializing in diagnostics, treatment and follow-up of cancers.
SOUTH SAN FRANCISCO, Calif., July 16, 2019 -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel.
Integrated BioTherapeutics (IBT) has been awarded a Phase I Small Business Innovative Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the NIH. The company will receive $550,000 for work to take place over the next two years.. The award is entitled Development of Therapeutic Pan-Filovirus Macaque Monoclonal Antibodies and the principal investigator is Dr. Sven Enterlein, Assistant Director of Molecular Virology. Filoviruses, including the well known Ebola Virus, are classified as Category A Priority Pathogens by NIAID. No vaccines or effective therapies are currently available for use in humans against these viruses. In this grant, IBT will combine its proprietary engineered filovirus antigens with Trelliss CellSpot(TM) technology in order to isolate non-human primate monoclonal antibodies that provide broad protective efficacy. CellSpot(TM) is a powerful platform developed and patented by Trellis Bioscience, LLC. (www.trellisbio.com) ...
BETHESDA, Md., March 23, 2017 - Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that yesterday it closed on the $7.5 million financing it announced last Friday, March 17, 2017.. The Company sold to several institutional investors securities totaling 28,843,692 shares, comprised of 18,843,692 common shares at $.26 per share, and 10,000,000 shares of Class C Warrants pre-funded at the closing at $.25 cents per future exercisable shares, with a one cent per share additional payment to be made at the time of actual exercise of these warrants. This arrangement is to enable investors to avoid exceeding 4.99% ownership while still funding $7.5 million.. Additionally, the investors received five year Class A warrants to purchase up to approximately 21.6 million shares of common stock with an exercise price of $0.26 per share. They also will receive three month Class B warrants to purchase ...
Investor info Aeglea BioTherapeutics: researching enzyme treatment and therapeutic human engineered enzymes to help treat cancer and rare genetic disease.
AGLE: Get the latest Aeglea BioTherapeutics stock price and detailed information including AGLE news, historical charts and realtime prices.
The first therapeutic usage of phage was in 1919, to treat a child with severe dysentery. In a classic case of old-school science, the lead researchers (which included dHerelle) drank portions of the bacteriophage preparation the day before treating the child, to check the treatments safety in humans. The researchers didnt keel over, the child fully recovered within a few days, and further tests on other patients confirmed the result. In the 1930s and 1940s, bacteriophage preparations were developed and sold by major companies such as LOréal and the Eli Lilly Company. The development and mass production of antibiotics in the late 1940s halted research into phage therapy in the West, due to the efficacy of antibiotics. Research continued in the Soviet Union. Hundreds of studies were made on phage therapy, with the the largest carried out in Tbilisi in 1963-64, involving 30,000 children [1]. This study focused on the use of phage as a weekly-administered prophylactic against Shigella. The ...
Using an experimental treatment that involves the use of bacteriophages, or viruses that target bacteria specifically, the team has successfully treated Tom Patterson, PhD, a psychiatric professor at the UCSD School of Medicine.. In 2015, Patterson contracted what appeared at the time to be pancreatitis, but it was soon discovered by a team of specialist doctors in Frankfurt, Germany, that Patterson had contracted an extremely rare, dangerous, virulent, and antimicrobial-resistant strain of the Acinetobacter baumannii pathogen.. After attempting to treat Pattersons condition with an increasingly dangerous cocktail of potent and hazardous antibiotics, Pattersons health began to fail rapidly, at which point he was airlifted to Thornton Hospital, at UCSD. With doctors unable to stop the spread of Acinetobacter baumannii superbug, Patterson was eventually placed into a medical coma in January 2016.. In March of the same year, a research team began treating Patterson with a unique phage therapy ...
Cytokines such as tumor necrosis factor (TNF) are expressed at high levels in rheumatoid joint tissue, where they contribute significantly to inflammation and articular destruction. TNF was the first cytokine to be fully validated as a therapeutic target for rheumatoid arthritis (RA). In nearly a decade since anti-TNF agents-such as infliximab, etanercept and adalimumab-were launched as the first biologic therapies to be licensed for RA, much has been learnt about how and when in the disease course this class of drug can be used to achieve optimal therapeutic benefit. Other cytokine targets, such as interleukin (IL)-6 or IL-1, have also been validated and several are in the process of being tested. However, TNF is likely to remain the preferred target of first-line biologic therapy for the foreseeable future as, in populations with active RA despite ongoing, nonbiologic, DMARD therapy, biologic inhibition of either IL-6 or IL-1 demonstrates no obviously superior outcomes to TNF blockade. Furthermore,
Cytokines such as tumor necrosis factor (TNF) are expressed at high levels in rheumatoid joint tissue, where they contribute significantly to inflammation and articular destruction. TNF was the first cytokine to be fully validated as a therapeutic target for rheumatoid arthritis (RA). In nearly a decade since anti-TNF agents-such as infliximab, etanercept and adalimumab-were launched as the first biologic therapies to be licensed for RA, much has been learnt about how and when in the disease course this class of drug can be used to achieve optimal therapeutic benefit. Other cytokine targets, such as interleukin (IL)-6 or IL-1, have also been validated and several are in the process of being tested. However, TNF is likely to remain the preferred target of first-line biologic therapy for the foreseeable future as, in populations with active RA despite ongoing, nonbiologic, DMARD therapy, biologic inhibition of either IL-6 or IL-1 demonstrates no obviously superior outcomes to TNF blockade. Furthermore,
Most authorities recommend starting biological agents upon failure of at least one disease-modifying agent in patients with rheumatoid arthritis. However, owing to the absence of head-to-head studies, there is little guidance about which biological to select. Still, the practicing clinician has to decide. This review explores the application of published evidence to practice, discussing the goals of treatment, the (in) ability to predict individual responses to therapy, and the potential value of indirect comparisons. We suggest that cycling of biological agents, until remission is achieved or until the most effective agent for that individual patient is determined, deserves consideration in the current stage of knowledge.
Questions addressing in whom and when to perform LTI screening, and chemoprophylaxis regimens and duration, were answered correctly by 93 and 94% of respondents, respectively. In contrast, questions concerning the action to be taken in the case of negative TT and the tests that should be requested for screening were only answered correctly by 25 and 36% of respondents, respectively.. Discussion. This survey of a wide range of medical specialists involved in the administration of biologics revealed a low degree of adherence to the recommendations of the Spanish Consensus Document on the Prevention and Treatment of Tuberculosis in Patients who are Candidates for Biological Treatment.16 Only 56% of respondents showed acceptable adherence to the recommendations. In 98% of cases, LTI screening was performed in the respondents own hospital, and this was the only variable associated with better adherence to the consensus. The percentage of respondents who conduct the screening themselves and their ...
Results We included 223 RA patients (79.4% of female, mean ± SD disease duration of 8.9±8.6 years). The mean age was 54±10.9 years, 70.8% rheumatoid factor (RF) positive, 84.4% anti-citrullinated protein antibody (ACPA) positive and 68.1% had radiographic damages. The mean DAS 28 was 5.5±2.6; 71% of patients received corticosteroids (mean 7mg per day of equivalent prednisone) and 63% methotrexate (mean 17.8mg per week). No patient had pain or other sinus or dental symptoms. Before biologic agent initiation, systematic dental and sinus screening revealed an oral infection in 31.5% of patients (dental: 20.2% and sinus: 14.8%). In univariate analysis, active smoking was associated with a higher risk of oral infection (OR=2.16 [1.02-4.57], p=0.038) and methotrexate with a lower rate (OR=0.43 [0.23-0.81], p=0.006). Corticosteroid, disease duration, DAS 28, RF, ACPA and structural damages were not associated with oral infection. No significant association was confirmed with oral infection using ...
With inward migration to Northern Ireland increasing, the prevalence of many opportunistic infections is likely to change. Updated guidelines on opportunistic infections in inflammatory bowel disease (IBD) were published by the European Crohns and Colitis Organisation in 2014. We set out to assess adherence to these guidelines in fifty patients with IBD before commencing biological therapy. Fifty sequential patients starting biological therapies were identified and their medical records were reviewed. Over 80% of patients were appropriately screened for tuberculosis, hepatitis B, hepatitis C and HIV but HBVcore antibody levels were uncommonly checked (22%). Varicella zoster serological (VZVIgG) screening seemed high at 60% but documentation of previous exposure was suboptimal. EBV screening was sporadic with only 20% being checked. Serum and tissue cytomegalovirus testing was performed in most cases of UC but with debate continuing on the optimum approach to this, it was inconsistent. Many of ...
ECCO - European Crohn´s and Colitis Organisation. The European Crohn\s and Colitis Organisation is a highly active non-profit association focusing on Inflammatory Bowel Diseases (IBD).
Objective: To survey the current status and problems of cooperation between clinics and hospitals in Okayama Prefecture, Japan for the treatment of rheumatoid arthritis (RA). Methods: We distributed a questionnaire to 300 of the 983 Okayama Prefecture clinics that had either an internal medicine or orthopedic surgery department, from December 2013 to February 2014. The questionnaire covered practice pattern for RA treatment in clinics, current status of the hospital and clinic cooperation, and acceptance of the biologic therapy. Results: One hundred clinics responded to the questionnaire. Seventy percent of the clinics reported making referrals to rheumatologists before the initiation of RA treatment, and half of the other 30% of the clinics administered methotrexate as the first-line treatment for RA by their own decision. Sixty-six clinics cooperated with flagship hospitals, conducting medical and laboratory examinations, providing prescriptions, and treating common diseases of patients. These ...
Results A total of 3880 patients (75.3% women) with a mean age of 51.3 years started non-biological DMARDs. After 5 years, 234 patients (6.0%) initiated biological DMARD therapy in 17.5±13.9 months. Differences in the socio demographic and pharmacological characteristics between the two groups of treatment are shown in the table 1. The use of glucocorticoids was associated with a greater risk of biological DMARD initiation (OR: 2.49; 95% CI: 1.658-3.732; p,0.001), while the use of methotrexate (OR: 0.04; 95% CI: 0.014-0.108; p,0.001) and chloroquine (OR: 0.13; 95% CI: 0.092-0.187; p,0.001) reduced the risk of initiation. ...
Palmoplantar psoriasis (PP) and palmoplantar pustulosis (PPP) are diseases affecting the hands and/or feet that can cause marked physical discomfort and functional disability. The tumor necrosis factor-alpha antagonists adalimumab, etanercept, and infliximab, the interleukin (IL)-17A inhibitors ixekizumab and secukinumab, and the IL-23 or IL-12/IL-23 inhibitors guselkumab and ustekinumab have been well studied for the treatment of moderate to severe plaque psoriasis. Less is known about the efficacy and safety of these agents for the treatment of PP (hyperkeratotic and pustular forms) and PPP. The aim of this review was to investigate the efficacy of biologic therapy for the treatment of hyperkeratotic PP, pustular PP, and PPP.A systematic search of the medical electronic databases (Medline, Embase, and Cochrane Library) was conducted to identify studies or case reports which both used biologic therapy for the treatment of hyperkeratotic PP, pustular PP, and PPP and reported treatment ...
The way the radiation therapy is given depends on the type and stage of the cancer being treated. External and internal radiation therapy are used to treat penile cancer.. Chemotherapy. Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). When chemotherapy is placed directly onto the skin (topical chemotherapy) or into the cerebrospinal fluid, an organ, or a body cavity such as the abdomen, the drugs mainly affect cancer cells in those areas (regional chemotherapy). The way the chemotherapy is given depends on the type and stage of the cancer being treated.. Topical chemotherapy may be used to treat stage 0 penile cancer.. See Drugs Approved for Penile Cancer for more information.. Biologic therapy. Biologic therapy is a ...
TY - JOUR. T1 - Pseudomonas aeruginosa: the potential to immunise against infection. AU - Sedlak-Weinstein, L.. AU - Kyd, Jennelle. AU - Foxwell, Ruth. PY - 2005. Y1 - 2005. M3 - Article. VL - 5. SP - 967. EP - 982. JO - Expert Opinions in Biological Therapies. JF - Expert Opinions in Biological Therapies. SN - 1471-2598. ER - ...